Full Press Release Details
SAN FRANCISCO , March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time .
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/ . The web broadcast of the conference call will be available for replay through April 12, 2025 .
To access the conference call, please pre-register at Nektar Earnings Call Registration . All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California . For further information, visit www.nektar.com and follow Nektar on LinkedIn.
For Investors: Vivian Wu of Nektar Therapeutics (628) 895-0661
For Media: Madelin Hawtin LifeSci Communications 603-714-2638 [email protected]
SOURCE Nektar Therapeutics